Comparing medications for NMOSD
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with NMOSD, a rare autoimmune condition affecting the nerves.
- You tested positive for the AQP4 antibody with a special blood test.
- You are 18 years or older.
- You are able to attend study visits and follow the procedures.
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
- You do not have active hepatitis B, hepatitis C, or untreated tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial studies satralizumab in children ages 2 to 11 with a specific type of NMOSD caused by AQP4 antibodies. It aims to see how well the medicine prevents attacks and is safe over time.
This study tests a medicine called ravulizumab to see if it lowers certain proteins in the blood that may indicate nerve damage in people with NMOSD. If you have NMOSD, this study could help track how well the treatment works.
This study tests a new medicine called ravulizumab (an infusion) to reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition affecting the optic nerve and spinal cord. The trial is specifically enrolling adults in China who have had recent disease activity.
This study follows people with NMOSD (a rare autoimmune disease affecting the brain and spinal cord) to learn more about the condition and how it affects patients over time. It involves regular check-ups and MRI scans, with the goal of improving future care and treatment.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
Hear when a new NMOSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.